BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 10195384)

  • 1. Appearance of anti TSH-receptor antibodies and clinical Graves' disease after radioiodine therapy for hyperfunctioning thyroid adenoma.
    Regalbuto C; Salamone S; Scollo C; Vigneri R; Pezzino V
    J Endocrinol Invest; 1999 Feb; 22(2):147-50. PubMed ID: 10195384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study.
    Laurberg P; Wallin G; Tallstedt L; Abraham-Nordling M; Lundell G; Tørring O
    Eur J Endocrinol; 2008 Jan; 158(1):69-75. PubMed ID: 18166819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Appearance of thyroid stimulating antibody and Graves' disease after radioiodine therapy for toxic nodular goitre.
    Chiovato L; Santini F; Vitti P; Bendinelli G; Pinchera A
    Clin Endocrinol (Oxf); 1994 Jun; 40(6):803-6. PubMed ID: 8033373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antithyroid drugs inhibit radioiodine-induced increases in thyroid autoantibodies in hyperthyroid Graves' disease.
    Nakazato N; Yoshida K; Mori K; Kiso Y; Sayama N; Tani JI; Nakagawa Y; Ito S
    Thyroid; 1999 Aug; 9(8):775-9. PubMed ID: 10482369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thyrotropin receptor antibodies and Graves' disease, a side-effect of 131I treatment in patients with nontoxic goiter.
    Nygaard B; Knudsen JH; Hegedüs L; Scient AV; Hansen JE
    J Clin Endocrinol Metab; 1997 Sep; 82(9):2926-30. PubMed ID: 9284721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of thyroid function in Graves' patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage.
    Chiovato L; Fiore E; Vitti P; Rocchi R; Rago T; Dokic D; Latrofa F; Mammoli C; Lippi F; Ceccarelli C; Pinchera A
    J Clin Endocrinol Metab; 1998 Jan; 83(1):40-6. PubMed ID: 9435414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistent Graves' hyperthyroidism despite rapid negative conversion of thyroid-stimulating hormone-binding inhibitory immunoglobulin assay results: a case report.
    Ohara N; Kaneko M; Kitazawa M; Uemura Y; Minagawa S; Miyakoshi M; Kaneko K; Kamoi K
    J Med Case Rep; 2017 Feb; 11(1):32. PubMed ID: 28162094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case of TSH receptor antibody-positive hyperthyroidism with functioning metastases of thyroid carcinoma.
    Ishihara T; Ikekubo K; Shimodahira M; Iwakura T; Kobayashi M; Hino M; Oobayashi M; Kohno K; Kimura K; Kawamura S; Kurahachi H
    Endocr J; 2002 Apr; 49(2):241-5. PubMed ID: 12081245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical results of anti-inflammatory therapy in Graves' ophthalmopathy and association with thyroidal autoantibodies.
    Eckstein AK; Plicht M; Lax H; Hirche H; Quadbeck B; Mann K; Steuhl KP; Esser J; Morgenthaler NG
    Clin Endocrinol (Oxf); 2004 Nov; 61(5):612-8. PubMed ID: 15521965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thyroid-stimulating antibody and TSH-binding inhibitor immunoglobulin in 277 Graves' patients and in 686 normal subjects.
    Takasu N; Oshiro C; Akamine H; Komiya I; Nagata A; Sato Y; Yoshimura H; Ito K
    J Endocrinol Invest; 1997 Sep; 20(8):452-61. PubMed ID: 9364248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assays of TSH-receptor antibodies in 576 patients with various thyroid disorders: their incidence, significance and clinical usefulness.
    Macchia E; Concetti R; Borgoni F; Cetani F; Fenzi GF; Pinchera A
    Autoimmunity; 1989; 3(2):103-12. PubMed ID: 2577491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A case of pulmonary metastatic thyroid cancer complicated with Graves' disease.
    Suzuki K; Nakagawa O; Aizawa Y
    Endocr J; 2001 Apr; 48(2):175-9. PubMed ID: 11456264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thyrotropin receptor autoantibodies are associated with continued thyrotropin suppression in treated euthyroid Graves' disease patients.
    Brokken LJ; Wiersinga WM; Prummel MF
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4135-8. PubMed ID: 12970276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease.
    Quadbeck B; Hoermann R; Roggenbuck U; Hahn S; Mann K; Janssen OE;
    Thyroid; 2005 Sep; 15(9):1047-54. PubMed ID: 16187913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of 1 alpha-hydroxyvitamin D3 on serum levels of thyroid hormones in hyperthyroid patients with untreated Graves' disease.
    Kawakami-Tani T; Fukawa E; Tanaka H; Abe Y; Makino I
    Metabolism; 1997 Oct; 46(10):1184-8. PubMed ID: 9322804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Graves' ophthalmopathy in the absence of elevated free thyroxine and triiodothyronine levels: prevalence, natural history, and thyrotropin receptor antibody levels.
    Khoo DH; Eng PH; Ho SC; Tai ES; Morgenthaler NG; Seah LL; Fong KS; Chee SP; Choo CT; Aw SE
    Thyroid; 2000 Dec; 10(12):1093-100. PubMed ID: 11201855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The usefulness of thyroid size and TSH receptor antibody (TRAb) determinations in predicting the effectiveness of tiamazole and I-131 treatment for Graves-Basedow's disease.
    Bojarska-Szmygin A; Janicki K; Pietura R; Janicka L
    Ann Univ Mariae Curie Sklodowska Med; 2003; 58(1):242-7. PubMed ID: 15314993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of methimazole with or without exogenous L-thyroxine on serum concentrations of thyrotropin (TSH) receptor antibodies in patients with Graves' disease.
    Rittmaster RS; Zwicker H; Abbott EC; Douglas R; Givner ML; Gupta MK; Lehmann L; Reddy S; Salisbury SR; Shlossberg AH; Tan MH; York SE
    J Clin Endocrinol Metab; 1996 Sep; 81(9):3283-8. PubMed ID: 8784084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Remission of Graves' hyperthyroidism predicted by smooth decreases of thyroid-stimulating antibody and thyrotropin-binding inhibitor immunoglobulin during antithyroid drug treatment.
    Takasu N; Yamashiro K; Komiya I; Ochi Y; Sato Y; Nagata A
    Thyroid; 2000 Oct; 10(10):891-6. PubMed ID: 11081255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pretreatment with betamethasone of patients with Graves' disease given radioiodine therapy: thyroid autoantibody responses and outcome of therapy.
    Gamstedt A; Karlsson A
    J Clin Endocrinol Metab; 1991 Jul; 73(1):125-31. PubMed ID: 2045463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.